Reddy , Chairman , Dr . Reddy ’ s Laboratories Ltd ., India , Mr Glenn Saldanha , Chairman and Managing Director , Glenmark Pharmaceuticals Ltd ., India and Dr Murtaza Khorakiwala , Managing Director of Wockardt .
In his keynote , Dr Paul Stoffels , Worldwide Chairman of Pharma , Chief Scientific Officer , Johnson & Johnson , USA , said , “ Pharmaceutical innovation has already delivered significant contribution to the society as in the past probably half of the life expectancies , was generated due to hygiene measures and half of it is due to innovation . The future has never been this brighter for medical sciences than it is today . If you look at the abilities of the new pathways the new insights and also the technological platforms ; I think we should be able to do a lot more . We are working towards significant collaborations around the world to have impact on the diseases going from cancer to tuberculosis and from interventional cardiology to consumer products .”
While addressing the concern on the investment on R & D , Dr . Vasanth Narasimhan , Global Head of Drug Development & CMO , Novartis , Switzerland said , “ The Bio Technology industry faces a challenge in getting the returns on huge investments they make on the Research and Development . The pharmaceutical & Biotech industry around the world invests almost a US $ 150 Billion and the question we have to answer is how efficiently we can use the funds and how the companies can get the returns for our investors .”
“ Each successful drug development today starts with a discovery or an invention followed by many years of development , creating a market and getting the drug to be actually used by the ethical community . I lived through this myself , I have seen that it took two generations of medical doctors to adopt MRI and use it where it is more apt to provide information needed ,” said Nobel Laureate , Prof Kurt Wuthrich , Scripps Research Institute ,
USA in his keynote at BioAsia 2017 .
The panel discussion on Enabling Innovation discussed about solving complex problems with innovation model and Executing an innovation model . It also deliberated on the pitfalls to avoid . The panel was chaired by Padma Shri Mr BVR Mohan Reddy , Founder & Chairman , Cyient . Other eminent panelists included Dr Renu Swarup , MD , BIRAC , Dept . of Biotechnology Dr Murtaza Khorakiwala , Managing Director , Wockhardt , India , Mr . Ranjit Shahani , Chairman & MD , Novartis India , Prof . Pramod P Wangikar , Professor in Charge , Wadhwani Research Center for Bioengineering , IIT Bombay , Ms . Amiee Aloi , Deputy Vice President , International Advocacy , PhRMA , USA , Dr Malathi Lakhshmikumaran , Director & Practice Head - Life Sciences Group , Lakshmikumaran & Sridharan Attorneys , India . The session was moderated by Padma Shri Dr D Balasubramanian , Distinguished Scientist & Director Emeritus -
BIOVOICENEWS . COM 27